Portola Pharmaceuticals Funding Round

5/7/2007

Venture Equity

$70,000,000

Series C

Portola plans to use the proceeds to advance the development of its two clinical candidates: PRT054021, an oral Factor Xa inhibitor, and PRT060128, an IV and oral ADP receptor antagonist, both of which are directed at validated targets (targets for which there is a drug on the market). Based on the recently announced positive data from a Phase II study of PRT054021, Portola plans to advance the program into further clinical trials. Portola has completed its Phase I clinical studies for both the IV and oral formulations of its second clinical program, PRT060128, and is currently planning its Phase II program which will begin in the second half of 2007.

Acquired or Merged

Biopharmaceutical

270 E. Grand Ave.
South San Francisco, CA 94080
USA

Portola Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola has two drug candidates in clinical development.